Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity
For stable pwMS, ocrelizumab discontinuation after about 30 months on-treatment appears safe short-term, though vigilant monitoring is warranted beyond 2 years off-treatment due to potential delayed reactivation.
Authors
- S Gingele
- Sandra Nay (ORCID: https://orcid.org/0000-0002-4986-1181)
- T. Skripuletz
- Philipp Schwenkenbecher (ORCID: https://orcid.org/0000-0002-1260-1650)
- Franz Felix Konen (ORCID: https://orcid.org/0000-0002-8609-5674)
- Franziska Axhausen
- Pauline Mühlenbrock
- Konstantin Fritz Jendretzky
- Stephanie Wolff
- Lea Martha Grote-Levi
- Steffen Pfeuffer
- Sven G Meuth
Institutions
- Justus-Liebig-Universität Gießen (DE)
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1136/jnnp-2025-337944
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00